The clinical development of obinutuzumab for the treatment of follicular lymphoma

por Ma, Barbara, Ujjani, Chaitra
Publicado 2017

Vaccinations in CLL: implications for COVID-19

por Shadman, Mazyar, Ujjani, Chaitra
Publicado 2021

Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat

por Raychaudhuri, Ruben, Ujjani, Chaitra
Publicado 2022

Primary effusion lymphoma: current perspectives

por Narkhede, Mayur, Arora, Shagun, Ujjani, Chaitra
Publicado 2018

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

por Lai, Catherine, Kandahari, Adrese Michael, Ujjani, Chaitra
Publicado 2019

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient

por Hill, Joshua A., Ujjani, Chaitra S., Greninger, Alexander L., Shadman, Mazyar, Gopal, Ajay K.
Publicado 2021

Concurrent Diagnosis of Chronic Myeloid Leukemia and Follicular Lymphoma: An Unreported Presentation

por Starr, Amy G., Jonna, Sushma R., Chahine, Joeffrey J., Kallakury, Bhaskar V., Ujjani, Chaitra S.
Publicado 2018

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma

por Younes, Anas, Burke, John M., Diefenbach, Catherine, Ferrari, Silvia, Khan, Cyrus, Sharman, Jeff P., Tani, Monica, Ujjani, Chaitra, Vitolo, Umberto, Yuen, Sam, Raval, Aparna, Shivhare, Mahesh, Nielsen, Tina G., Sellam, Gila, Gilbertson, Michael
Publicado 2022

Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures

por Graf, Solomon A., Lynch, Ryan C., Ujjani, Chaitra S., Gooley, Ted A, Coffey, David G., Cowan, Andrew J., Smith, Stephen D., Shadman, Mazyar, Warren, Edus H., Libby, Edward, Godwin, Colin D., Greninger, Alexander L, Fromm, Jonathan R., Gopal, Ajay K
Publicado 2021

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study

por Iovino, Lorenzo, Wu, Qian Vicky, Voutsinas, Jenna, Panaite, Lorena, Mullane, Erin, Lynch, Ryan C., Ujjani, Chaitra, Smith, Stephen D., Gopal, Ajay K., Till, Brian G., Milano, Filippo, Chow, Victor, Gauthier, Jordan, Turtle, Cameron J., Maloney, David G., Shadman, Mazyar
Publicado 2022

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL

por Graf, Solomon A., Lynch, Ryan C., Ujjani, Chaitra S., Gooley, Ted A., Rasmussen, Heather, Coffey, David G., Cowan, Andrew J., Smith, Stephen D., Shadman, Mazyar, Warren, Edus H., Libby, Edward N., Greninger, Alexander L., Fromm, Jonathan R., Gopal, Ajay K.
Publicado 2022

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

por Neelapu, Sattva S., Dickinson, Michael, Munoz, Javier, Ulrickson, Matthew L., Thieblemont, Catherine, Oluwole, Olalekan O., Herrera, Alex F., Ujjani, Chaitra S., Lin, Yi, Riedell, Peter A., Kekre, Natasha, de Vos, Sven, Lui, Christine, Milletti, Francesca, Dong, Jinghui, Xu, Hairong, Chavez, Julio C.
Publicado 2022

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

por Ujjani, Chaitra, Mato, Anthony, Hill, Brian T, Allan, John N, Lansigan, Frederick, Jacobs, Ryan, Skarbnik, Alan, Tuncer, Hande, Pagel, John, Brander, Danielle, Cheson, Bruce, Barr, Paul, Roeker, Lindsey E, Pu, Jeffrey, Shah, Nirav N, Goy, Andre, Schuster, Stephen J, Lamanna, Nicole, Sehgal, Alison, Tam, Constantine S, Shadman, Mazyar
Publicado 2020

P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM S...

por Jurczak, Wojciech, Luigi Zinzani, Pier, Eyre, Toby A., Cheah, Chan Y., Ujjani, Chaitra S., Izutsu, Koji, MA, Shuo, Flinn, Ian, Alencar, Alvaro J., Lewis, David, Patel, Krish, Maddocks, Kami, Wang, Yucai, Munir, Talha, Zelenetz, Andrew D., Balbas, Minna, Tsai, Donald E., Wang, Chunxiao, Wang, Michael L., Shah, Nirav N.
Publicado 2023

The Impact of B-Cell-Directed Therapy on Sars-Cov-2 Vaccine Efficacy in CLL: 1-Year Follow up

por Ujjani, Chaitra S., Poh, Christina, Tu, Brian, Lee, Sydney, Selke, Stacy, Zhu, Haiying, Shadman, Mazyar, Lynch, Ryan C., Huang, Meei-Li W, Gopal, Ajay K., Warren, Edus H., Till, Brian G., Smith, Stephen D, Sperling, Amy, Hill, Joshua A., Stevenson, Philip, Nielsen, Leslie, Gooley, Ted A., Greninger, Alexander L
Publicado 2022

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

por Lynch, Ryan C., Poh, Christina, Ujjani, Chaitra S., Warren, Edus H., Smith, Stephen D., Shadman, Mazyar, Morris, Karolyn, Lee, Sydney, Rasmussen, Heather, Ottemiller, Susan, Shelby, Megan, Keo, Sarith, Verni, Kaitlin, Kurtz, David M., Alizadeh, Ash A., Chabon, Jacob J., Hogan, Gregory J., Schulz, Andre, Gooley, Ted, Voutsinas, Jenna M., Gopal, Ajay K.
Publicado 2022

P1097: CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY

por Shadman, Mazyar, Yeung, Cecilia, Redman, Mary W, Yun Lee, Sang, Hoon Lee, Dong, Ra, Susan, Qian, David H, Dezube, Bruce, Chapuis, Aude, Green, Damian, Cowan, Andrew, Cassaday, Ryan, Kiem, Hans-Peter, Warren, Houston E, Milano, Filippo, Gauthier, Jordan, Hirayama, Alexandre, Kwok, Mary, Ujjani, Chaitra, Maloney, David, Gopal, Ajay, Till, Brian
Publicado 2023

P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL

por Rhodes, Joanna, Shadman, Mazyar, Lamanna, Nicole, S. Manzoor, Beenish, Coombs, Catherine, Ghosh, Nilanjan, H. Tuncer, Hande, Emechebe, Dozie, R. Brown, Jennifer, Alhasani, Hasan, Leslie, Lori, Roeker, Lindsey, Ujjani, Chaitra, Eichhorst, Barbara, Fleury, Isabelle, Skarbnik, Alan, T. Hill, Brian, Lansigan, Frederick, M. Barr, Paul, Davids, Matthew, Fox, Christopher, Choi, Yun, E. Jensen, Christopher, Schuh, Anna, Kennard, Kaitlin, Jawaid, Dureshahwar, Pivneva, Irina, Watson, Talissa, Eyre, Toby
Publicado 2023

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

por Mato, Anthony R., Nabhan, Chadhi, Thompson, Meghan C., Lamanna, Nicole, Brander, Danielle M., Hill, Brian, Howlett, Christina, Skarbnik, Alan, Cheson, Bruce D., Zent, Clive, Pu, Jeffrey, Kiselev, Pavel, Goy, Andre, Claxton, David, Isaac, Krista, Kennard, Kaitlin H., Timlin, Colleen, Landsburg, Daniel, Winter, Allison, Nasta, Sunita D., Bachow, Spencer H., Schuster, Stephen J., Dorsey, Colleen, Svoboda, Jakub, Barr, Paul, Ujjani, Chaitra S.
Publicado 2018

T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total meta...

por Lynch, Ryan C., Alig, Stefan, Ujjani, Chaitra S., Poh, Christina, Warren, Edus H., Smith, Stephen D., Shadman, Mazyar, Shustov, Andrei, Till, Brian, Raghunathan, Vikram M., Tseng, Yolanda, Coye, Hilary, Shelby, Megan, Ottemiller, Susan, Keo, Sarith, Verni, Kaitlin, Du, Hongyan, Vandermeer, Jackie, Gaston, Ashley, Rasmussen, Heather, Gulhane, Avanti, Chen, Delphine L., Martin, Paul, Marzbani, Edmond, Voutsinas, Jenna, Alizadeh, Ash A., Gopal, Ajay K.
Publicado 2022